Navigation Links
Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008

BEIJING, May 7 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that Mr. Weidong Yin, CEO, and Ms. Helen Yang, International Business Manager, are scheduled to present at the Brean Murray, Carret & Co. All-Cap All-China Conference on Monday, May 19, 2008 at 10:15 a.m. Eastern Standard Time at the Waldorf Astoria in New York, NY.

Ms. Nan Wang, Vice President, and Ms. Vanessa Wu, Senior Financial Manager, are scheduled to present at the Roth China Discovery Tour 2008 the same day at 5:20 p.m. Beijing Time at the Regent Hotel in Beijing, China.

Web cast of the Company's presentation at the Brean Murray, Carret & Co. All-Cap All-China Conference will be available by going to the investor relations section of Sinovac's Web site at . A replay of the presentation will be available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM)(H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, . To be added to our distribution list, please email:

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:


Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910



Stephanie Carrington

The Ruth Group

Tel: +1-646-536-7017



Janine McCargo

The Ruth Group

Tel: +1-646-536-7033


SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Biotech Holds Annual General Meeting
2. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
3. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
4. Sinovac Announces Adjournment of Annual General Meeting
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Closes $9.75 Million Private Placement
7. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Sinovac Announces Postponement of Annual General Meeting
10. Entrust Chairman, President and CEO Bill Conner to Present at 8th Annual State of Technology Luncheon
11. Sigma-Aldrich to Present at the Baird 2008 Growth Stock Conference on Tuesday, May 13, 2008
Post Your Comments:
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and ... the "Global Voice Recognition Biometrics Market 2015-2019" ... --> The global voice recognition biometrics ... 2014-2019. --> --> ... has been prepared based on an in-depth market analysis ...
Breaking Biology News(10 mins):